

Juan V Guanira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3710496/publications.pdf>

Version: 2024-02-01

32
papers

3,361
citations

304743

22
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

3294
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluating the impact of policies recommending PrEP to subpopulations of men and transgender women who have sex with men based on demographic and behavioral risk factors. PLoS ONE, 2019, 14, e0222183.	2.5	1
2	The impact and cost-effectiveness of combined HIV prevention scenarios among transgender women sex-workers in Lima, Peru: a mathematical modelling study. Lancet Public Health, The, 2019, 4, e127-e136.	10.0	21
3	Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project. AIDS Research and Human Retroviruses, 2019, 35, 788-793.	1.1	8
4	Health Survey in a Peruvian health system (ENSSA). Revista De Saude Publica, 2019, 53, 33.	1.7	5
5	Brief Report: Cocaine Use and Pre-exposure Prophylaxis: Adherence, Care Engagement, and Kidney Function. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 78-82.	2.1	18
6	Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine. Clinical Infectious Diseases, 2018, 67, 411-419.	5.8	50
7	HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 466-472.	1.2	4
8	The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men. AIDS and Behavior, 2018, 22, 3673-3680.	2.7	33
9	International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status. Sexually Transmitted Diseases, 2017, 44, 306-309.	1.7	0
10	Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 177-182.	2.1	25
11	Towards a fair consideration of PrEP as part of combination HIV prevention in Latin America. Journal of the International AIDS Society, 2016, 19, 21113.	3.0	32
12	The Safety of Tenofovir+Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 281-286.	2.1	25
13	Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV,the, 2016, 3, e521-e528.	4.7	66
14	Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, S226-S229.	2.1	33
15	Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study. AIDS and Behavior, 2016, 20, 1535-1540.	2.7	33
16	Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension. Clinical Infectious Diseases, 2016, 62, 1172-1177.	5.8	40
17	HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV,the, 2015, 2, e512-e519.	4.7	225
18	Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Infectious Diseases, 2015, 61, 572-580.	5.8	132

#	ARTICLE	IF	CITATIONS
19	Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring. <i>Journal of Infectious Diseases</i> , 2015, 212, 1402-1406.	4.0	62
20	Streamlining HIV Testing for HIV Preexposure Prophylaxis. <i>Journal of Clinical Microbiology</i> , 2015, 53, 179-183.	3.9	10
21	Reply to Boyd et al. <i>Clinical Infectious Diseases</i> , 2015, 60, 327-327.	5.8	0
22	Syphilis Predicts HIV Incidence Among Men and Transgender Women Who Have Sex With Men in a Preexposure Prophylaxis Trial. <i>Clinical Infectious Diseases</i> , 2014, 59, 1020-1026.	5.8	132
23	Study Product Adherence Measurement in the iPrEx Placebo-Controlled Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 530-537.	2.1	73
24	HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 468-475.	9.1	128
25	Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 820-829.	9.1	1,039
26	HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial. <i>Journal of Infectious Diseases</i> , 2014, 210, 1217-1227.	4.0	68
27	Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. <i>Aids</i> , 2014, 28, 851-859.	2.2	123
28	Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men. <i>Science Translational Medicine</i> , 2012, 4, 151ra125.	12.4	807
29	Quality of Life Among Individuals with HIV Starting Antiretroviral Therapy in Diverse Resource-Limited Areas of the World. <i>AIDS and Behavior</i> , 2012, 16, 266-277.	2.7	34
30	Hepatitis B Infection and Association with Other Sexually Transmitted Infections Among Men Who Have Sex with Men in Peru. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 83, 194-200.	1.4	29
31	Prevalence and Correlates of Human Herpesvirus 8 Infection Among Peruvian Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 557-562.	2.1	14
32	Association of Herpes Simplex Virus Type 2 Infection and Syphilis with Human Immunodeficiency Virus Infection among Men Who Have Sex with Men in Peru. <i>Journal of Infectious Diseases</i> , 2006, 194, 1459-1466.	4.0	91